Further enhancing therapeutic efficacy, the next-generation BiTE candidate BC261 has demonstrated superior tumor eradication in preclinical models, achieving approximately 30-fold greater T cell infiltration even against tumors with low STEAP1 expression levels [159]. The gene discussed is STEAP1; the disease is neoplasm.